Takeda Grabs Shire At Last After Long Pursuit

May 08 2018

• By Ian Haydock

Listen to this article

Takeda and Shire see their £46bn combination bringing commercial and pipeline strengths across multiple therapeutic areas, along with opportunities for cost synergies and strengthening in key geographic markets.

Arrow flying to target with radial motion blur — TAKEDA FINALLY HITS TARGET WITH SHIRE • Source: Shutterstock

Shire PLC's acceptance, as expected, of a £48.17 per share acquisition offer from determined pursuer Takeda Pharmaceutical Co. Ltd., paves the way for a roughly £46bn ($62.45bn) deal that will create a new force just inside the global pharma top 10, and also marks both the biggest ever M&A transaction by the Japanese pharma sector and the largest overseas buy-out in any sector in Japan.

The combined sales of the merged group are estimated to be around $30bn, based on recent annual sales, and Takeda's...

More from Japan

Progress Or Hype? A Decade Of Cell Therapy In Japan
Aug 26 2024
• By Lisa Takagi
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Japan Pharma Layoffs: Takeda And Others Implementing Broad Cuts
Aug 08 2024
• By Lisa Takagi
Several major Japanese firms, including Takeda, are planning layoffs at home and elsewhere as they make efforts to streamline their business and costs and cope with R&D and commercial challenges.
Japan Results Roundup: Strong Mainstays, Currency Windfall Help Top Line
Aug 06 2024
• By Lisa Takagi
Results from the top Japanese pharma firms in the fiscal first quarter were marked mainly by strong global performances for mainstay products and significant currency effects due to the continued weakness of the yen, although forex concerns are rising. Eisai's Alzheimer's drug Leqembi also gained momentum, particularly in the US.
Win Some, Lose Some: Amid Otsuka-Jnana Deal, Delaware Court Favors Lupin For gJynarque
Aug 05 2024
• By Vibha Ravi
Otsuka Pharma’s acquisition of Jnana seems like a win for its pipeline, but the Japanese major faced a setback in a Delaware District Court where the judge’s opinion put challenger Lupin closer to a generic to its Jynarque (tolvaptan)

More from Focus On Asia

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2
Oct 14 2025
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval
Mar 10 2025
• By Dexter Jie Yan
The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.
As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS
Mar 10 2025
• By Mandy Jackson
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.